PEDRO HENRIQUE XAVIER NABUCO DE ARAUJO

(Fonte: Lattes)
Índice h a partir de 2011
7
Lattes
ResearcherID
ORCID
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/61 - Laboratório de Pesquisa em Cirurgia Torácica, Hospital das Clínicas, Faculdade de Medicina

Filtros

Limpar filtros

Configurações

Tipo de produção: conferenceObject ×

Resultados de Busca

Agora exibindo 1 - 10 de 18
  • conferenceObject
    A Comparative Cost Analysis Study of Robotic and Video-Assisted Lobectomy: Results of Randomized Controlled Trial (Bravo Trial)
    (2021) TERRA, R.; TRINDADE, J.; CAMPOLINA, A.; ARAUJO, P. H. De; CAMPOS, J. R. De; PEGO-FERNANDES, P.
  • conferenceObject
    THE IMPACT OF PLEURAL CATHETER POSITION ON THE SUCCESS OF BEDSIDE PLEURODESIS
    (2014) TERRA, Ricardo Mingarini; ARAUJO, Pedro Henrique Xavier Nabuco de; CHATE, Rodrigo Caruso; PEGO-FERNANDES, Paulo
  • conferenceObject
    Predictors of Hospital Discharge in Cancer Patients with Pericardial Effusion Who Undergo Surgical Pericardial Drainage
    (2015) KAZANTZIS, Thamara; TERRA, Ricardo M.; BIBAS, Benoit J.; LAURICELLA, Leticia L.; ARAUJO, Pedro N.; DELA-VEGA, Alberto J. M.; PEGO-FERNANDES, Paulo M.
  • conferenceObject
    WEB-BASED THORACIC SURGERY ONLINE COURSE: INCREASING ACCESS, CONNECTING PEOPLE AND DECREASING INEQUALITIES. FEASIBILITY RESULTS.
    (2014) TERRA, Ricardo Mingarini; ARAUJO, Pedro Henrique Xavier Nabuco de; MARIANI, Alessandro Wasun; VEGA, Alberto Jorge Monteiro Dela; PEGO-FERNANDES, Paulo
  • conferenceObject
    Efficacy and safety of adjuvant chemotherapy in lung cancer: Real-world evidence
    (2019) ROITBERG, F. S. R.; NEFFA, M. F. B. V.; BONADIO, R. R. C. C.; HARADA, G.; MENDOZA, E. Z.; MAK, M. P.; TAKAHASHI, T. K.; MARTINS, R. E.; MESQUITA, C.; SANTINI, F. C.; ARAUJO, P. H. X. N. de; LAURICELLA, L. L.; PRADO, G. F.; TAKAGAKI, T. Y.; MELLO, E. S. de; GABRIELLI, F.; CARVALHO, H. D. A. de Andrade; TERRA, R. M.; CASTRO JR., G. de
  • conferenceObject
    EGFR GENOTYPING AND EPIDEMIOLOGY, CLINICAL AND PATHOLOGICAL FEATURES IN 191 PATIENTS WITH METASTATIC PULMONARY ADENOCARCINOMA IN SAO PAULO - BRAZIL.
    (2013) CASTRO JR., Gilberto; TAKAHASHI, Tiago K.; CAIRES-LIMA, Rafael; PROTASIO, Bruno M.; MAIA, Manuel C. D. F.; SOARES, Ibere C.; ROITBERG, Felipe S. R.; MARINI, Andrea M.; MARTINS, Renata E.; TAKAGAKI, Teresa Y.; ARAUJO, Pedro H. X. N.; TERRA, Ricardo M.; SHIANG, Christina; SIQUEIRA, Sheila A. C.; MELLO, Evandro S.; ALVES, Venancio A.; HOFF, Paulo M.
  • conferenceObject
    Learning Curve in Robotic-Assisted Thoracoscopic Pulmonary Resection: Experience of a Brazilian Surgeon
    (2021) TERRA, R.; SOARES, M.; LIMA, L.; LAURICELLA, L.; ARAUJO, P. H. De; CAMPOS, J. R. De; PEGO-FERNANDES, P.
  • conferenceObject
    Expected Variability of C-Reactive Protein after Pulmonary Resections: Which Factors Are Associated with Their Normal Variation?
    (2015) AUGUSTO, Diogo G.; SAMPAIO-FONSECA, Hugo V.; TERRA, Ricardo M.; BIBAS, Benoit J.; LUAMOTO, Leandro R.; ARAUJO, Pedro N.; MARIANI, Alessandro W.; PEGO-FERNANDES, Paulo M.
  • conferenceObject
    What Happens to the Pleural Space Affected by Malignant Effusion after Bedside Pleurodesis?
    (2015) TERRA, Ricardo M.; ARAUJO, Pedro N.; SANTOS, Thiago S.; CHATE, Rdrigo C.; PAIVA, Antonio L.; PEGO-FERNANDES, Paulo M.
  • conferenceObject
    REFERRAL OF LUNG CANCER PATIENTS TO SPECIALIZED CLINICAL ONCOLOGY CARE: INSTITUTO DO CANCER DO ESTADO DE SAO PAULO 2010-2011
    (2012) CAIRES-LIMA, Rafael; TAKAHASHI, Tiago K.; MAK, Milena P.; ROITBERG, Felipe S. R.; TEIXEIRA, Carlos H. A.; MESQUITA, Cristiane S.; MARINI, Andrea M.; MARTINS, Renata E.; TAKAGAKI, Tereza Y.; ARAUJO, Pedro N.; FEHER, Olavo; HOFF, Paulo M.; CASTRO JR., Gilberto De
    Background: Lung cancer is the leading cause of death from malignancy in Western countries. To achieve better outcomes and improve quality of care, it is essential to know both patients and disease characteristics. Here we aim to describe epidemiological and tumor characteristics and their impact on survival outcomes, of patients admitted at Instituto do Câncer de Estado de São Paulo (ICESP) between January 2010 and July 2011. Methods: It is a retrospective, descriptive, and uninstitutional study, of patients diagnosed histologically with lung cancer, consecutively admitted at ICESP between January 2010 and July 2011. Overall survival was the main endpoint. Frequencies were compared using chi-square test. Survival was estimated using the Kaplan-Meier methods, and the curves were compared by the log-rank test. This study was approved by the local IRB. Results and Conclusion: 232 patients (pts) were included in this analysis: median age 65y (24-91), 57% male, 56% ECOG 0 - 1, and 83% previous or current smokers. Non small cell lung cancer (NSCLC) was the most common histologic type (213 pts, 92%). Small cell lung cancer (SCLC) was diagnosed in 18 pts (7.6%) and only one (0.4%) was a case of a carcinoid tumor. Regarding NSCLC histologic subtypes, adenocarcinoma was the most common (130 pts, 61%), followed by squamous cell carcinoma (63 pts, 30%) and large cell carcinoma (5 pts, 2%). In 17 pts (7%), it was not possible to determine the subtype, even with immunohistochemistry. In terms of staging, 155 pts (71%) with NSCLC presented metastatic disease (stage IV) at diagnosis, 27 pts (12%) were staged as IIIB, 15 pts (10%) IIIA, 8 pts (3.5%) II and 8 pts (3.5%) I. Among patients with SCLC, six (33%) had localized disease (LD) and 12 (67%) had extensive disease (ED). Analyzing only stage IV NSCLC pts, 123 (79%) were treated with first line chemotherapy, 56 (36%)with second line and 13 (8%) with third line systemic therapies; ECOG 0 - 2 NSCLC pts were more likely to be exposed to second-line therapies (46% vs 36%; p = 0.0002). In a median follow-up of 9.5 mo, median overall survival (mOS) was 9 mo for all pts in this analysis. Regarding NSCLC, in patients with stage I and II mOS was not reached (100% and 68% in 2 years for stage I and II, respectively). In patients with stage IIIA, IIIB and IV, the median OS was 15.2, 11.4 and 7 mo, respectively (p-trend = 0.0002). According to ECOG-PS, mOS was 11.3, 6.3, 4.1, and 2.2 mo for NSCLC pts with ECOG 1, 2, 3 and 4, respectively (p-trend < 0.0001). For SCLC pts, mOS was 12.9 mo among those with LD versus 4.9 mo in ED (HR 3.1; 95% CI 1.1 - 8.6; p = 0.02). Lung cancer survival rate remains poor. As expected, clinical stage and performance status were important prognostic factors. Primary prevention strategies (quitting smoking) and early diagnosis (screening) may be useful in this scenario.